Secondary Logo

Institutional members access full text with Ovid®

Intracameral Bevacizumab (Avastin) for Neovascular Glaucoma: A Pilot Study in 6 Patients

Duch, Susana MD, PhD; Buchacra, Oscar MD; Milla, Elena MD, PhD; Andreu, David MD, PhD; Tellez, Jesús MD

doi: 10.1097/IJG.0b013e318170a747
Case Report

Purpose To describe the use of intracameral bevacizumab (ICB) Avastin in neovascular glaucoma (NVG) as the first maneuver before pan retinal photocoagulation and/or filtering surgery.

Methods Between June 2006 and May 2007, 6 consecutive patients with NVG underwent intracameral injection of bevacizumab (1.25 mg/0.05 mL) as the initial treatment of NVG. Pre-ICB and post-ICB anterior segment photography, iris fluoresceingraphy when possible, gonioscopy with peripheral anterior synechiae (PAS), neovascular membrane (NVM) extension grading, as well as intraocular pressure (IOP) changes during treatment were recorded. All patients were followed for at least 7 months.

Results ICB resulted in a marked regression of anterior segment neovascularization with IOP control without filtering surgery in 2 cases. When PAS extended <330 degrees without previous glaucoma, no filtering surgery was needed to control IOP<18 mm Hg. Iris neovascularization extension had no prognostic value in terms of IOP control. After vascular regression following the administration of ICB, filtering surgery with drainage implants or trabeculectomy were performed when needed with no added difficulties owing to the underlying NVG. No macroscopic signs of corneal toxicity were detected, even when ICB injection had to be repeated. In this case, the time elapsed for the neovascular membrane to reappear at the anterior segment was 3 months.

Conclusion ICB resulted in a rapid regression of the iris and angle neovascularization, which permitted to halt the progression of PAS process. This pilot study shows that intracameral injection of bevacizumab may be a helpful adjunct for the surgical treatment of NVG.

Department of Ophthalmology, Instituto Condal de Oftalmología (ICO), Instituto Universitario Dexeus, Barcelona, Spain

Funding: None.

Conflict of Interest: The authors have no proprietary interest in the development or marketing in any of the materials used in this study.

Reprints: Susana Duch, MD, PhD, Department of Ophthalmology, Instituto Condal de Oftalmología (ICO), Instituto Universitario Dexeus, Calatrava 10-12, 5° 2°, 08017 Barcelona, Spain (e-mail:

Received for publication November 27, 2007; accepted February 24, 2008

Presented in part at the Spanish Glaucoma Society Meeting, Madrid, Spain, March 2 to 3, 2007 and at the XXXV Meeting of the Canarian Society of Ophthalmology, Tenerife, Spain, June 7 to 8, 2007.

© 2009 Lippincott Williams & Wilkins, Inc.